Cargando…

A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors

INTRODUCTION: Use of adeno-associated virus (AAV) vectors is complicated by host immune responses that can limit transgene expression. Recent clinical trials using AAV vectors to deliver HIV broadly neutralizing antibodies (bNAbs) by intramuscular administration resulted in poor expression with anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davis-Gardner, Meredith E., Weber, Jesse A., Xie, Jun, Pekrun, Katja, Alexander, Eric A., Weisgrau, Kim L., Furlott, Jessica R., Rakasz, Eva G., Kay, Mark A., Gao, Guangping, Farzan, Michael, Gardner, Matthew R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161250/ https://www.ncbi.nlm.nih.gov/pubmed/37153616 http://dx.doi.org/10.3389/fimmu.2023.1105617

Ejemplares similares

Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV
por: Martinez-Navio, José M., et al.
Publicado: (2020)

Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies
por: Gardner, Matthew R., et al.
Publicado: (2019)

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies
por: Davis-Gardner, Meredith E., et al.
Publicado: (2020)

Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions
por: Weber, Thomas
Publicado: (2021)

Liver-Directed but Not Muscle-Directed AAV-Antibody Gene Transfer Limits Humoral Immune Responses in Rhesus Monkeys
por: Fuchs, Sebastian P., et al.
Publicado: (2019)

Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors
por: Tseng, Yu-Shan, et al.
Publicado: (2014)

T Cell-Mediated Immune Responses to AAV and AAV Vectors
por: Ertl, Hildegund C. J.
Publicado: (2021)

Successful Transduction with AAV Vectors after Selective Depletion of Anti-AAV Antibodies by Immunoadsorption
por: Orlowski, Alejandro, et al.
Publicado: (2020)

Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?
por: Zhan, Wei, et al.
Publicado: (2021)

A Rapid Immunization Strategy with a Live-Attenuated Tetravalent Dengue Vaccine Elicits Protective Neutralizing Antibody Responses in Non-Human Primates
por: Ambuel, Yuping, et al.
Publicado: (2014)

High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes
por: Gardner, Matthew R., et al.
Publicado: (2022)

Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques
por: Pedreño-Lopez, Nuria, et al.
Publicado: (2021)

Selection of rAAV vectors that cross the human blood-brain barrier and target the central nervous system using a transwell model
por: Song, Ren, et al.
Publicado: (2022)

Contribution to HIV Prevention and Treatment by Antibody-Mediated Effector Function and Advances in Broadly Neutralizing Antibody Delivery by Vectored Immunoprophylaxis
por: Phelps, Meredith, et al.
Publicado: (2021)

AAV Vectors Vaccines Against Infectious Diseases
por: Nieto, Karen, et al.
Publicado: (2014)

The AAV capsid can influence the epigenetic marking of rAAV delivered episomal genomes in a species dependent manner
por: Gonzalez-Sandoval, Adriana, et al.
Publicado: (2023)

Editorial: “AAV Gene Therapy: Immunology and Immunotherapeutics”
por: Martinez-Navio, José M., et al.
Publicado: (2021)

rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
por: Esmagambetov, Ilias B., et al.
Publicado: (2023)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
por: Hamilton, Bradley A., et al.
Publicado: (2021)

Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
por: Ronzitti, Giuseppe, et al.
Publicado: (2020)

Engineering antibody-like inhibitors to prevent and treat HIV-1 infection
por: Gardner, Matthew R., et al.
Publicado: (2017)

VectorMOD: Method for Bottom-Up Proteomic Characterization of rAAV Capsid Post-Translational Modifications and Vector Impurities
por: Rumachik, Neil G., et al.
Publicado: (2021)

Targeting the somatosensory system with AAV9 and AAV2retro viral vectors
por: Skorput, Alexander G. J., et al.
Publicado: (2022)

Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside
por: Ferreira, Valerie, et al.
Publicado: (2014)

Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
por: Basner-Tschakarjan, Etiena, et al.
Publicado: (2014)

Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity
por: Termini, James M., et al.
Publicado: (2020)

AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6
por: Denard, Jérôme, et al.
Publicado: (2018)

Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells
por: Davey, Brianna C., et al.
Publicado: (2022)

Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction
por: Muhuri, Manish, et al.
Publicado: (2021)

CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector
por: Murlidharan, Giridhar, et al.
Publicado: (2016)

AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System
por: Marino, Marika, et al.
Publicado: (2022)

Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
por: Basner-Tschakarjan, Etiena, et al.
Publicado: (2014)

Effect of CpG Depletion of Vector Genome on CD8(+) T Cell Responses in AAV Gene Therapy
por: Bertolini, Thais B., et al.
Publicado: (2021)

Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
por: Fitzpatrick, Zachary, et al.
Publicado: (2018)

Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors
por: Kuklik, Juliane, et al.
Publicado: (2021)

Recombinant AAV Vectors for Enhanced Expression of Authentic IgG
por: Fuchs, Sebastian P., et al.
Publicado: (2016)

Optimized AAV rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer
por: Selot, Ruchita, et al.
Publicado: (2017)

Assessment of anti-CD20 antibody pre-treatment for augmentation of CAR-T cell therapy in SIV-infected rhesus macaques
por: Pampusch, Mary S., et al.
Publicado: (2023)

Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors
por: Zeltner, Nadja, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_p74fj413i0hobb0e7g1n3n8ugh